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Background: Wilson’s disease (WD), a rare cause of neuropsychiatric deterioration, is associated with mutations in
the ATP7B gene. Prion diseases are also rare causes of neuropsychiatric deterioration that can occur sporadically
without an identifiable cause, or can be attributed to mutations in the PRNP gene.
Case presentation: Here we describe a biological “experiment of nature” in which a patient presented with severe
neuropsychiatric decline and strong biochemical evidence of WD. Genetic analysis revealed that he was a
compound heterozygote for two ATP7B sequence variants (c.2165dupT, p.Arg723Glufs*32; and c.4039G > A, p.
Gly1347Ser), the first having been reported once previously, and the second being novel. In addition, the patient
was heterozygous for a PRNP variant, c.160G > A, p.Gly54Ser, that has been reported in a neuropsychiatric patient
only once previously in association with a similarly severe clinical course of neuropsychiatric disease and early age
of onset, but no accompanying information on ATP7B genotype. Of particular interest was the observation that the
patient’s older sister, who carried the same ATP7B genotype and laboratory evidence for biochemical WD but was
clinically asymptomatic, lacked the PRNP variant allele.
Conclusions: We propose that synergism may occur between at least some allelic variants of ATP7B and PRNP,
possibly exerted through effects on cellular copper metabolism.
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Movement disorderBackground
Wilson’s disease (WD, OMIM #277900) is an autosomal
recessive genetic disorder of copper metabolism [1],
with an estimated global prevalence as high as 1 in
30,000 [2], implying a Hardy-Weinberg allele frequency
of approximately 0.6% (carrier frequency of about 1 in
90). The implicated gene in WD is ATP7B, which en-
codes a copper-transporting P-type ATPase, ATP7B,
and is mainly expressed in hepatic, renal, ocular and
neural tissues. More than 500 ATP7B variant alleles
have been described since its discovery in 1993 (http://
www.wilsondisease.med.ualberta.ca/database.asp) [3,4].* Correspondence: tarnopol@mcmaster.ca
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reproduction in any medium, provided the orThe primary pathophysiologic effect of these genotypes is
multi-organ deposition of copper with mainly hepatic,
neurologic and psychiatric clinical manifestations. Forty to
fifty percent of WD patients have hepatic symptoms as the
initial manifestation, although neurologic and psychiatric
presentations are also relatively common, and about 50%
of all patients will have neuropsychiatric manifestations
during their disease course, including movement disorders
(bradykinesia, rigidity, tremor, dystonia), ataxia, cognitive
impairment, depression and psychosis. The classical ap-
proach to diagnosis of WD relies upon recognition of
neurological and/or hepatic features, finding of Kayser-
Fleischer rings (~ 2/3 of those with neurological disease),
and measurement of altered biochemical markers in the
serum (low copper and ceruloplasmin) and/or urine (high
24 h copper excretion) [5]. However, with increasingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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spectrum of ATP7B and ATP7B, and declining costs for
DNA analysis, genetic testing is increasingly used for de-
finitive differential diagnosis of the disease [6].
Prion diseases (OMIM #123400, #137440, #600072) also
result in progressive, irreversible neurodegeneration, with
cognitive and psychiatric manifestations that can overlap
significantly with the phenotype of WD. Although clinical
presentation of prion disease (including genetic forms) is
highly varied, neurological and/or psychiatric manifesta-
tions are a consistent feature in nearly all cases. Human
prion diseases usually occur sporadically, or very rarely
through infectious transmission, but can also arise (in 5–
15% of cases) in association with phenotypically dominant
mutations in the autosomal gene (PRNP) that encodes the
prion glycoprotein PrP [7,8]. Etiologically, prion diseases
are classified as proteopathies, with pathobiology triggered
by post-translational conversion of the normal conform-
ation of PrP (PrPC) into a misfolded isoform (PrPSc) that is
deposited as insoluble aggregates particularly in neural tis-
sues(Prusiner, 1998). Although the normal physiological
functions of PrPC are less well understood than those of
ATP7B, evidence is accumulating to support the hypoth-
esis that these functions are related to copper, particularly
in the brain [9-11].
Here we report the finding of nonsynonymous coding-
sequence variants in both ATP7B and PRNP genes in a
patient with rapidly progressive neurological WD. We postu-
late that synergistic interaction between the observed ATP7B
and PRNP variants, mediated by effects of their encoded
variant proteins on copper metabolism, may underlie the pa-
tient’s severe course of neurologic deterioration.
Case presentation
A 34-year-old man from the Punjab region of India, who
had immigrated to Canada in 2010, having developed a
gradual onset of a bilateral intention tremor, worsening
over the course of 7 years. This was initially diagnosed as
spinocerebellar ataxia. Over the previous 2 years he had
experienced various progressive psychiatric disturbances
including severe depression, anxiety and mood lability.
This constellation of symptoms had been variously diag-
nosed as depression, bipolar disorder and bipolar affective
disorder, for which trials of several mood stabilizers, anti-
depressants and antipsychotics had been attempted with
limited, modest, short-term benefits.
In the year following emigration, the patient experienced
a rapid decline in overall function, marked by an incident
involving a trip and a fall. He began experiencing gait in-
stability and imbalance, rigidity, scanning speech, dyspha-
gia, and eventually choking episodes. The neuropsychiatric
symptoms worsened over several months as the patient
concomitantly experienced restlessness, sexual disinhib-
ition, aggression and social inappropriateness. By thesummer of 2011, his balance and rigidity had further deteri-
orated preventing him from ambulating, and thus prompt-
ing his family to seek further medical assessment. His
symptoms culminated in an in-hospital episode of acute
dystonia in July of 2011, prompting admission. At the time
of admission following this episode, the patient was on lith-
ium, quetiapine, propranolol, and zopiclone.
The patient’s family history revealed no known consan-
guinity and the only significant neurological disorder was
in the now deceased proband’s maternal grandfather who
developed a rapidly progressive gait disturbance and cog-
nitive impairment at age 62 y and died ~ 8 months after
the onset with a first generation CT scan showing “cere-
bral atrophy”. Neurological examinations of the proband’s
mother (age 61 y), father (age 62 y) and older sister (age
39 y) were normal, aside from a mild intention tremor in
the mother. Physical examination revealed normal vital signs
but the patient was agitated, with labile mood and sporadic
emotional outbursts. Detailed neurologic examination re-
vealed the presence of scanning dysarthria, severe rigidity in
both upper and lower extremities, hyperreflexia in arms and
legs, appendicular dystonia, dysdiadochokinesia and truncal
ataxia. Ophthalmologic examination did not reveal Kayser-
Fleischer rings by fundoscopy; however, the patient was un-
able to be positioned for a slit-lamp examination because of
severe rigidity and tremor. Cardiac, respiratory and abdom-
inal examinations were unremarkable, with no evidence of
hepatosplenomegaly or ascites. There were no stigmata of
acute or chronic liver disease, and no asterixis.
Brain MRI revealed generalized atrophy in addition to
“giant panda sign” at the level of the midbrain, consistent
with Wilson’s disease. Abdominal ultrasound showed
coarse liver echogenicity and irregular contours with a
height of 10.2 cm in the mid-clavicular line, suggestive of
cirrhosis. Liver biopsy confirmed grade 2–3 fibrosis and
bridging, with Orcein stain negative for copper deposition
(no direct biochemical measurement). A complete biochem-
ical and pathologic workup was negative for viral hepatitis,
alpha-1 anti-trypsin disease, hemochromatosis, and auto-
immune hepatitis. Echocardiogram showed normal ejection
fraction with no hypertrophy or abnormal deposition.
Routine biochemical investigations of blood and urine
were within normal limits, including a complete blood
count, extended electrolyte panel and tests of renal func-
tion. Liver enzymes were normal, as were tests of synthetic
liver function. Tests of copper metabolism showed a mark-
edly low serum ceruloplasmin of 0.05 (normal, > 0.21 g/L),
low serum copper of 3.4 (normal, > 11 μmol/L), and high
24-hour urine copper of 1.8 (normal, < 0.6 μmol/24 h).
The patient was then treated with standard chelating
therapy and zinc supplementation. Initially, he was started
on penicillamine, but experienced commonly described ad-
verse effects of severe neurologic deterioration and fever,
warranting a change to trientene, which he is still taking
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fold to 17.7 μmol after 3 weeks of chelation. The patient’s
psychiatric issues largely resolved but he did remain on the
aforementioned psychotropic medications. He has made
small gains in terms of recovery of neurologic function, but
remains mute, wheelchair bound and dystonic, in spite of
modest cognitive recovery when assessed one year after ini-
tiation of treatment.
Based upon the patient’s history of a severely progressive
neurological disorder with basal-ganglia symptoms/signs,
ataxia and a major antecedent psychiatric presentation,
diagnoses of either WD or genetic prion disease were con-
sidered, and DNA sequence analysis of ATP7B and PRNP
was requested. Analysis of the ATP7B gene was performed
by the University of Chicago Genetic Services Laboratory
in Chicago, Illinois through Sanger sequencing of all coding
exons and intron/exon boundaries (reference sequence:
GenBank NM_000053, transcript variant 1). Sanger se-
quencing of the single coding exon (exon 2) of the PRNP
gene was performed by the Canadian Creutzfeldt-Jakob
Disease Surveillance System, Public Health Agency of
Canada (reference sequence: GenBank M13899).
DNA sequencing revealed that the patient was a com-
pound heterozygote for two different ATP7B sequence
variants (c.2165dupT; c.4039G >A). His PRNP gene lacked
known pathogenic sequence variants, but he was hetero-
zygous for a non-synonymous sequence variant (c.160G >
A, p.Gly54Ser), as well as homozygous (ATG/ATG) for a
common, non-pathogenic single-nucleotide polymorph-
ism (c.385A >G, p.Met129Val) at codon 129.
A family study (Figure 1) revealed that the parents of
the proband were each carriers of one of the two differ-
ent ATP7B mutations (c.2165dupT in the father, and
c.4039G >A in the mother). His mother carried the PRNP
c.160G >A variant and was heterozygous ATG/GTG (Met/
Val) at codon 129, while his father did not carry the PRNP
c.160G >A variant and was homozygous ATG/ATG (Met +
Met) at codon 129. The sister of the proband was found to
be a compound heterozygote for the same two ATP7B vari-
ants carried by her brother, while lacking the c.160G >A
variant and being heterozygous ATG/GTG (Met +Val) at
codon 129 of PRNP. However, despite exhibiting a classical
biochemical phenotype for Wilson’s disease with a low
serum copper level of 2.1 μmol/L, a low ceruloplasmin of
0.12 g/L, and a high 24 h urine copper level of 1.1 μmol
(normal values as above), she was asymptomatic, with a nor-
mal MRI and neurological examination.
Conclusions
We describe a case of severe, rapidly progressive neuro-
logical WD in a patient who was found to carry heterozy-
gous allelic variants in the two genes (ATP7B and PRNP)
that have been linked to WD and prion disease, respect-
ively. We consider it remarkable that the patient’s sisterdid not display a WD clinical phenotype (and normal
MRI), in spite of having the same ATP7B genotype and
biochemical abnormalities. Without confirmation of the
genotype of the deceased maternal grandfather it is speculative
as to whether or not he had the maternal genotype (PRNP
c.160G>A; ATP7B c.4039G>A) that explained the later onset
of a severe phenotypically similar neurological decline.
These findings may be interpreted to argue for rather
impressive heterogeneity of genetic penetrance among
siblings with identical ATP7B genotypes, conceivably
mediated in part by genetic differences between the sib-
lings at other, unexamined genetic loci. However, it is of
interest that both ATP7B and PrP proteins have been
biologically linked to cellular systems for copper hand-
ling and regulation in the brain [9,12]. Thus, despite the
acknowledged limitations of our study based on its small
size, we feel that the current findings, including both the
severity of the patient’s disease and the phenotypic dis-
cordance between himself and his sibling, merit raising
the question of possible synergistic interaction between
the biochemical and/or cellular effects of the proteins
encoded by the variant alleles we observed in these two
genes, with an unknown mechanism but perhaps medi-
ated by effects on copper metabolism. Other reports
have linked variation in the progress of Wilson’s disease
with the common p.Met129Val polymorphism in PRNP
[13,14]. However, as discussed further below, the p.
Gly54Ser PRNP variant we identified in this family is lo-
cated in a different domain of the PrP protein that is dir-
ectly implicated in copper metabolism.
The two cation-transporting P-type ATPases, ATP7A
and ATP7B, are vital in both the incorporation of copper
into the plasma protein ceruloplasmin and the biliary ex-
cretion of copper [12]. Structurally, the N-terminal re-
gion of these enzymes contains 6 heavy-metal-associated
domains that each span approximately 70 amino acid
residues and are involved in binding copper directly
[15]. The C-terminal region contains 8 transmembrane
(TM) domains, an E1-E2 ATPase domain, and a haloacid
dehydrogenase domain that contains the catalytic active
site. One of the two ATP7B variants observed in our pa-
tient, c.2165dupT in exon 8, results in a frame-shifted
coding sequence, and is predicted to encode a truncated
polypeptide with the heterologous sequence beginning
with an Arg723Glu substitution within the TM2-TM3
cytosolic loop (Ala718–His724) and ending 32 amino
acids downstream with a premature stop codon. This vari-
ant has been reported once previously in the literature,
and is recorded twice in the Wilson disease mutation
database [4,16]. The other variant, c.4039G > A in exon
20, leads to a Gly→ Ser substitution at the evolutionarily
conserved Gly1347 residue within the non-cytosolic TM7-
TM8 loop (Gly1341–Gln1351). This variant has not been
reported previously but is predicted to “affect protein
Figure 1 Pedigree showing ATP7B and PRNP mutations among the proband and family members. Pedigree was created using the
Progeny Free Online Pedigree Tool (http://www.progenygenetics.com/).
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damaging” by PolyPhen-2 (score = 1.00)(NP_000044.2). Thus,
both of the encoded variant ATP7B proteins are pre-
dicted to be functionally hypomorphic, accounting for
the proband and his sister’s low levels of serum copper
and ceruloplasmin as well as elevated level of urine
copper. Each of the variants independently affected copper
metabolism to an expected lesser degree for each of the par-
ents (mother = c.4039G >A; father = c.2165dupT), showed
below normal concentrations of both serum copper and
ceruloplasmin.
Although the biochemical and cellular functions of PrPC
are not yet as well-described as those of ATP7A and
ATP7B, the N-terminal half of this protein is flexibly un-
structured and probably multifunctional [17], and contains
a domain of contiguous amino acid sequence repeat units,
highly conserved among mammals [18]. In humans this
domain, which spans PrP residues Pro51–Gln91, consists
of 5 repeat units including an N-terminal nonapeptide
lacking histidine (Pro-Gln-Gly-Gly-Gly-Trp-Gly-Gln) and
4 tandem copies of a His-containing octapeptide (Pro-His-
Gly-Gly-Gly-Trp-Gly-Gln). The 4 octapeptides have been
found to bind copper cooperatively with a physiologically
relevant range of affinities, through coordination at the
His residues as well as two deprotonated backbone amide
nitrogens and a carbonyl oxygen of the following two Gly
residues [9,19,20].
Physiologically, evidence is strong that PrPC functions
as a cuproprotein, potentially playing one or more roles
as an antioxidant, chaperone, transporter, enzyme, orsensor, particularly at the neuronal synapse [9-11]. PRNP
variant alleles with insertions [21], or deletions [22], of octa-
peptide repeat units result in prion disease in humans. For
insertion alleles, disease phenotype (particularly age of on-
set) appears to be correlated with the number of extra
octapeptide repeats; these phenotypic effects have been pro-
posed to be mediated in turn by effects on copper binding
behavior of the repeats [23]. In addition, experimental ani-
mal models of prion disease have been shown to be sensitive
to either reduced or elevated levels of copper [24,25]. How-
ever, the specific role(s) of PrPC in the copper-handling ma-
chinery of the brain remain incompletely understood.
The c.160G >A variant PRNP allele observed in our pa-
tient results in a predicted substitution of Ser for the sec-
ond Gly within the nonapeptide unit of the PrP octapeptide
repeat domain. In contrast with the 4 octapeptide units, the
nonapeptide unit does not contain His, and no specific
function has yet been proposed for it, including involve-
ment in the binding of copper. Thus, at this time we can-
not predict the precise biochemical or physiological effects
of the c.160G > A variant. However, given its high se-
quence similarity and position immediately adjacent to
the octapeptide-repeat array, as well as the observation
that the presence, position and sequence of the nona-
peptide unit are highly conserved among mammalian
species [18], it is worth considering the hypothesis that
the Gly54Ser substitution subtly alters the steric inter-
action of PrPC with copper, and that this altered inter-
action promotes the neuropathogenic effects of elevated
brain copper levels in WD.
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neuropsychiatric disease in an individual with the same
PRNP genotype as our proband (c.160G >A; codon 129
ATG/ATG), a 43-year-old female Ugandan patient of simi-
lar ethnogeographic background (South East Asian) pre-
sented with dysarthria, which progressed into non-fluent
dysphasia, progressive apraxia and extrapyramidal signs
[26]. Five years after disease onset, she was mute and in-
capable of ambulation, with death following some months
thereafter. At autopsy, widespread deposits of PrPSc were
observed with immunohistochemical analysis of cerebral
and cerebellar tissue, in a pattern not previously observed
in genetic prion diseases. Intriguingly, the c.160G >A vari-
ant was also found in a single healthy Gujarati individual
screened at the time of initial patient referral, and at very
low frequencies in reportedly healthy Pakistani, Chinese
and Middle-Eastern groups included in the CEPH human
genome diversity cell line panel. These findings strongly
suggest that the c.160G > A PRNP variant is not sufficient
in itself to cause prion disease, although the absence of evi-
dence for such pathogenic effects from the healthy control
populations does not completely exclude the possibility of
lower-penetrance effects on prion disease risk. However, we
agree with the authors of the above-mentioned study [26],
that this patient’s disease presentation remains incompletely
explained. It is tempting to suggest that abnormal copper
metabolism might have contributed to her clinical disease,
perhaps with the involvement of undocumented genetic
variation at ATP7B.
In summary, we suggest that the simultaneous pres-
ence of protein-coding sequence variants in ATP7B
and PRNP in a patient with neurological Wilson’s dis-
ease constitutes a serendipitous biological “experiment
of nature” that will be of interest both to clinicians
from a diagnostic perspective, and also to basic scien-
tists interested in the (patho)physiologic functions of
ATP7B and PrP, including potential biochemical or
metabolic synergistic effects mediated by copper me-
tabolism of the human brain.Consent
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